Replimune says FDA rejected its lead drug for skin cancer
Source: SeekingAlpha
2025-07-22 07:34:57 ET
More on Replimune Group
- Replimune Group, Inc. (REPL) Q4 2025 Earnings Call Transcript
- Replimune Group: Analysts Are More Optimistic Than The Market
- Replimune: Scope Goes Beyond That Of RP1 Oncolytic Targeting For Melanoma
- Replimune Group GAAP EPS of -$3.07 misses by $0.01
- Seeking Alpha’s Quant Rating on Replimune Group
Read the full article on Seeking Alpha
For further details see:
Replimune says FDA rejected its lead drug for skin cancer
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
7.97% G/L:
$5.02 Last:
609,269 Volume:
$4.90 Open:
REPL Latest News
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
